4basebio PLC
4BB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £159 | £84 | £87 | £76 |
| - Cash | £35 | £3 | £4 | £10 |
| + Debt | £15 | £10 | £3 | £2 |
| Enterprise Value | £139 | £91 | £86 | £68 |
| Revenue | £1 | £1 | £0 | £0 |
| % Growth | 84.4% | 88.8% | -20.7% | – |
| Gross Profit | £1 | £0 | £0 | £0 |
| % Margin | 67.5% | 67.2% | 89.2% | 79.6% |
| EBITDA | -£11 | -£7 | -£5 | -£3 |
| % Margin | -1,175.7% | -1,451.2% | -2,018.3% | -948.8% |
| Net Income | -£12 | -£8 | -£5 | -£3 |
| % Margin | -1,321.9% | -1,514.8% | -1,921.6% | -957.1% |
| EPS Diluted | -0.94 | -0.62 | -0.42 | -0.26 |
| % Growth | -51.6% | -47.6% | -61.5% | – |
| Operating Cash Flow | -£11 | -£6 | -£5 | -£3 |
| Capital Expenditures | -£2 | -£1 | -£2 | -£2 |
| Free Cash Flow | -£12 | -£8 | -£7 | -£4 |